AbbVie inks $2 billion deal with IGI, bags antibody to fight cancerÂ
HQ Team July 10, 2025: AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team July 10, 2025: AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to.
HQ Team April 14, 2023: SAB Biotherapeutics got a fast-track designation from the USFDA for its investigational drug to treat influenza in high-risk.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com